Authors
Zhongcheng Ke, Xiaoling Cheng, Yimin Niu, Xuwen Chai, Wenwen Fang, Ping Wang, Yan Gong, Zitong Zhu, Yibin Feng
Published in
Pharmaceutical development and technology. Pages 1-8. Nov 21, 2025. Epub Nov 21, 2025.
Abstract
The aim of this study was to develop an amorphous solid dispersion system utilizing meglumine (MG) as an alkalizing matrix to improve the dissolution rate and oral bioavailability of gambogic acid (GA). Solid dispersion of GA with MG (GA/MG-SD) was fabricated via solvent evaporation using an equal molar of quantity of GA/MG. Physicochemical characterization was conducted through FT-IR spectral analysis, DSC thermograms, PXRD patterns, and SEM imaging, and the contact angle and dissolution profiling also were determined. Pharmacokinetic evaluation was performed in SD rats to assess bioavailability enhancement. DSC analysis indicated disappeared crystal of GA and MG as no distinct peaks were observed. This was further evidenced by PXRD analysis. The dissolution of GA from GA/MG-SD reached 76.1% after 1 h in media (pH 6.8), compared to only 22.2% for free GA. The solubility and drug dissolution rate of GA/MG-SD were significantly higher than those of free GA (p < 0.01), and drug dissolution behavior fit in the Higuchi model. Furthermore, pharmacokinetic assessment demonstrated a 2.0-fold increase in AUC0-24 values compared to free GA, confirming improved systemic exposure. Overall, the MG-based dispersion strategy effectively transformed GA into an amorphous state with superior wettability, achieving concurrent enhancement of dissolution efficiency and oral bioavailability.
PMID:
41251228
Bibliographic data and abstract were imported from PubMed on 28 Nov 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0